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and veins: anatomical, physiologic, 
and pharmacological considerations
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Abstract 
Background: Cardiovascular disease remains a major health care challenge. The knowledge about the underlying 
mechanisms of the respective vascular disease etiologies has greatly expanded over the last decades. This includes 
the contribution of microRNAs, endogenous non‑coding RNA molecules, known to vastly influence gene expression. 
In addition, short interference RNA has been established as a mechanism to temporarily affect gene expression. This 
review discusses challenges relating to the design of a RNA interference therapy strategy for the modulation of vas‑
cular disease. Despite advances in medical and surgical therapies, atherosclerosis (ATH), aortic aneurysms (AA) are still 
associated with high morbidity and mortality. In addition, intimal hyperplasia (IH) remains a leading cause of late vein 
and prosthetic bypass graft failure. Pathomechanisms of all three entities include activation of endothelial cells (EC) 
and dedifferentiation of vascular smooth muscle cells (VSMC). RNA interference represents a promising technology 
that may be utilized to silence genes contributing to ATH, AA or IH. Successful RNAi delivery to the vessel wall faces 
multiple obstacles. These include the challenge of cell specific, targeted delivery of RNAi, anatomical barriers such as 
basal membrane, elastic laminae in arterial walls, multiple layers of VSMC, as well as adventitial tissues. Another major 
decision point is the route of delivery and potential methods of transfection. A plethora of transfection reagents and 
adjuncts have been described with varying efficacies and side effects. Timing and duration of RNAi therapy as well as 
target gene choice are further relevant aspects that need to be addressed in a temporo‑spatial fashion.
Conclusions: While multiple preclinical studies reported encouraging results of RNAi delivery to the vascular wall, it 
remains to be seen if a single target can be sufficient to the achieve clinically desirable changes in the injured vascular 
wall in humans. It might be necessary to achieve simultaneous and/or sequential silencing of multiple, synergistically 
acting target genes. Some advances in cell specific RNAi delivery have been made, but a reliable vascular cell specific 
transfection strategy is still missing. Also, off‑target effects of RNAi and unwanted effects of transfection agents on 
gene expression are challenges to be addressed. Close collaborative efforts between clinicians, geneticists, biologists, 
and chemical and medical engineers will be needed to provide tailored therapeutics for the various types of vascular 
diseases.
© The Author(s) 2017. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
MicroRNA (miRNA) and short interfering RNA 
(siRNA)
Short interfering RNA and miRNA are useful tools to 
temporarily suppress target genes. Different from siRNA, 
miRNA are endogenously occurring short RNAs heavily 
involved in regulating numerous cellular functions. A 
recent review provides a more in-depth comparison of 
siRNA and miRNA, including respective transfection 
modalities [1].
While siRNA usually is used to silence one specific 
gene, a single miRNA has the ability to affect expression 
of multiple genes. Approximately one-third of the genes 
are regulated by miRNA and it has been shown that 
several miRNA are able to bind to the identical 3′UTR 
region [2]. Various reviews summarized how different 
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miRNA clusters affect vascular biology [3, 4]. miRNA are 
small non-coding RNA molecules (~22 bp) that contain 
an imperfectly base-paired hairpin segment [5]. In con-
trast, siRNA are mostly exogenous and while similar in 
length, siRNA form perfectly complementary double-
strand structures [5]. After Drosha and Dicer mediated 
maturation, single-stranded miRNA enters the RNA-
induced silencing complex (RISC). Subsequently this 
complex directs the miRNA to the target mRNA resulting 
its translational repression [3, 4]. Additionally, miRNA 
have the ability to regulate gene transcription after their 
nuclear import [6]. Similar to miRNA, siRNA hybridizes 
with its target mRNA in RISC leading to its catalytic deg-
radation. We recently reviewed current siRNA targets for 
ATH, AA and IH and thus will focus here primarily on 
aspects of RNAi delivery to the vascular wall [7, 8].
Anatomical and physiological differences of vascular 
conduits and disease
The anatomy of arteries and veins reveals similarities yet 
also significant histological differences. The inner lining 
of arteries and veins (tunica intima) consists of a single 
layer of EC seated on a basement membrane (BM). The 
layers of the BM are composed of an intricate network 
consisting of various collagens types, glycoproteins and 
proteoglycans, and cell–cell, and cell–matrix interaction 
regulators such as integrins. Different from sinuses in 
the liver and spleen, which have a discontinuous BM and 
therefore promote extravasation of RNAi, the BM of large 
arteries and veins is continuous and provides an anatomi-
cal barrier. The BM is connected to a thin layer of suben-
dothelial connective tissue. Different from veins, arteries 
and arterioles also have as the outer margin of the tunica 
intima a prominent internal elastic membrane (lamina) 
with elastin containing fibers. This layer presents another 
physical barrier for RNAi for transmural delivery.
The next layer, tunica media is mostly comprised of 
circularly arranged smooth muscle cells with inter-
spersed reticular and elastic fibers. This layer’s thick-
ness varies significantly between veins and arteries. 
Naturally a thicker layer of SMC in larger arteries pro-
vides a greater challenge for a homogenous, transmu-
ral transfection when compared to a thin-walled vein 
graft. As mentioned before, VSMC appear less sus-
ceptible to RNAi compared to EC [9–12]. If VSMC are 
the designated primary target cells and in the absence 
of a technology to achieve VSMC-specific delivery, it 
is possible that a disproportionate amount of RNAi 
oligomers will transfect nearby EC. This needs to be 
factored into the silencing strategy as it could cause 
deleterious effects. This is especially the case if regula-
tors of apoptosis, cell cycle, or migration are targeted 
[13–15].
The outer most layer, tunica adventitia is made up of 
connective tissue. In large arteries an external elastic 
membrane may separate the tunica adventitia from the 
tunica media. Large arteries and veins receive additional 
blood supply via vasa vasorum, which enter from the 
adventitial site. Given the low oxygen content of venous 
blood, it is conceivable that large veins are more depend-
ent on vasa vasorum for their nutrient/oxygen supply 
than arteries. In the setting of vein graft implantation, that 
supply route may be disrupted. This may contribute to the 
formation of IH. It is also believed that vasa vasorum play 
a significant role in atherosclerosis progression [16].
Interestingly, vasa vasorum appear to cease to sup-
ply oxygenated blood to the arterial wall at the level of 
the  renal  arteries, which may help explain an increased 
incidence of aortic aneurysms in this region [17]. The 
expression of endothelial alpha(v)beta3 integrin was used 
to pharmacologically target vasa vasorum and thus mod-
ulate atherosclerosis [16].
Atherosclerosis
Atherosclerosis (ATH) by some is considered a chronic 
inflammatory condition that involves a complex interplay 
of immune and stromal cells, cytokines and enzymes. 
It is characterized by a disturbed loco-regional lipid 
metabolism, extracellular matrix organization, and cel-
lular homeostasis leading to lipid plaque build-up and 
ultimately risk for plaque rupture and vascular narrowing 
or occlusion [8, 18]. Hyperglycemia is further believed to 
induce VSMC resistance to apoptosis and thus contribut-
ing to diabetic vasculopathy [19]. Multiple potential tar-
gets for a siRNA therapy of ATH, AA, and IH have been 
identified, yet clinically convincing evidence of an effica-
cious therapy is lacking [7, 8].
A recent review from Welten et al. dissects the contri-
bution of various miRNA clusters to the maladaptive pro-
cesses of atherosclerosis and restenosis [20]. Prominent 
miRNA amongst those are miR-126, miR-155, the miRNA 
gene clusters 17-92, and miRNA 23/24/27, 143/145 [20]. 
Additionally, transcoronary gradients of anti-atheroscle-
rotic miR-126-3p and miR-145-5p were found to correlate 
with the extent of thin cap fibroatheromas [21]. miRNA-
210 is believed to enhance fibrous cap stability in athero-
sclerotic lesions [22]. miRNA targets for atherosclerosis 
were also recently reviewed elsewhere [23].
Intimal hyperplasia (IH)
In the case of IH in the setting of vein graft surgery and 
vascular implantation injury, synthetic VSMC migrate 
towards the lumen of the vessel. There, VSMC prolifer-
ate and secrete pro-inflammatory cytokines and extracel-
lular matrix proteins forming the bulk of the eventual IH 
lesion [7].
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miRNA have also shown to be involved in IH forma-
tion [24, 25]. One of the genes that has been shown to 
regulate the expression of multiple miRNA in VSMC is 
Thrombospondin 1 (TSP-1), a glycoprotein involved in 
cell–cell and cell–matrix contacts [25]. The most upreg-
ulated miRNA in response to TSP-1 was miR-512-3p, 
while the most downregulated miRNA was miR-25-5p. 
Interestingly, five members of the mir-17-92 cluster were 
downregulated [25].
Some strategies to attenuate IH aimed at attenuating 
VSMC proliferation after vascular injury [13, 26, 27]. 
While this seems to make physiologic sense, clinically the 
initial results have been disappointing. The largest, pro-
spective, randomized controlled trial in humans to date 
(PREVENT III) designed to attenuate vein graft failure by 
use of oligonucleotide anti-sense therapy targeting E2F, a 
transcription factor promoting G1/M transition, failed to 
show protection from IH [26, 27]. There has been a lot 
of debate as to why to the PREVENT III trial failed. Be 
it the degree or duration of gene silencing, or the target 
E2F itself. Another consideration is that EC are more sus-
ceptible to RNAi than VSMC under identical conditions 
[9–12]. Hence, it is conceivable, that bystander EC were 
transfected and their altered ability to proliferate in the 
setting of vascular injury may have contributed to the 
trial’s failure.
Anatomical proximity of EC and VSMC
Given the immediate proximity of EC and VSMC in the 
vascular bed, it appears a rather difficult task to deliver 
RNAi exclusively to one of the two cell fractions. In addi-
tion, particularly the arterial vessel wall consists of a thick 
muscular layer with multiple layers of VSMC stacked on 
top of each other. In order to achieve a transfection suc-
cess across all VSMC layers, a high dose of RNAi oligom-
ers as well as potent transfection agents [e.g. liposomal or 
cationic polymer based such as polyethyleneimine (PEI)] 
may have to be used [9, 28, 29]. This again may result 
in inadvertent transfection of other cells residing in the 
vascular wall including EC, pericytes, dendritic cells and 
fibroblasts. These cells have important roles in vascular 
homeostasis and in orchestrating the response to injury. 
Furthermore, the aforementioned transfection agents 
themselves elicit profound effects on the transcriptome 
of vascular cells thus additionally complicating the situ-
ation [29].
Distinct gene expression and stress response patterns 
of VSMC and EC from different vascular beds
Not surprisingly, relevant differences exist amongst the 
same cell type (EC or VSMC) within the separate vascular 
beds. A study comparing canine VSMCs within the aorta 
(Ao), branch pulmonary artery (bPA), main pulmonary 
artery (mPA) and inferior vena cava (IVC) revealed not 
only obvious histologic differences in layer thickness and 
cellular organization, but also significant protein expres-
sion differences with regards to smooth muscle actin 
(SMA), myosin heavy chain (MHC) and smooth muscle 
myosin heavy chain isoform 2 (SM2) [30].
Separately, differential expression patterns were found 
with regards to Hox4. Products of the hox gene fam-
ily regulate the cranio-caudad organization of the body 
during embryogenesis. Differential Hox4 expression has 
been found along the aorta in EC and VSMC of baboons. 
Thoracic EC and VSMC revealed higher Hox4 levels 
compared to corresponding abdominal aortic cells [31]. 
Further, human AAA specimens were found to have a 
significantly lower Hox4 expression when compared to 
healthy controls [31].
Another example is the protein testin, which was found 
to be differentially expressed in coronary and internal 
mammary arteries. Testin is a cytoskeleton-associated 
protein that localizes along actin stress fibers, at cell–cell-
contact areas, and at focal adhesion plaques. Testin was 
also found to have tumor suppressor gene function and 
may be relevant for EC function [32, 33]. Testin silenc-
ing in EC promoted oxidized-LDL-mediated monocyte 
adhesion to ECs, EC migration and the transendothelial 
migration of monocytes, while overexpression of testin 
mitigated these effects [33].
Aside from varying intrinsic protein expression pro-
files it could be shown that VSMC from different seg-
ments of the circulation respond distinctly to noxious 
stimuli. Oxidized low-density lipoprotein (OxLDL) treat-
ment in saphenous vein graft VSMC (SV-VSMC) led to 
an increase in proliferation and migration as well as NF-
kappa B activation. In contrast, OxLDL inhibited prolif-
eration and migration in coronary VSMC. In addition, 
significant differences in cytokine, chemokine extracellu-
lar matrix protein expression were noted between these 
cell groups [34].
In line with this are observations derived from in vitro 
experiments, which revealed that SV-VSMC were found 
to be significantly more proliferative and displayed a 
more migratory and invasive behavior than internal 
mammary artery VSMC [35].
Yet in contrast, human VSMC derived from athero-
sclerotic lesions of infragenicular arteries displayed sig-
nificantly increased rates of proliferation, adhesion, and 
migration as compared to human saphenous vein VSMC 
[36].
Also, the response to hypoxia appears to be different 
in arterial and venous SMC. While both cell fractions 
showed a decreased proliferative response to hypoxia, 
arterial SMC showed a significant upregulation of vas-
cular endothelial growth factor (VEGF-A), while venous 
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SMC did not. VEGF-R 2 expression was found to be 
upregulated in hypoxic venous SMC, but not in arte-
rial SMC [37]. The same investigators hypothesized that 
VEGF-A may be a target gene of mir-125b, 29a, and 
29b. Interestingly, hypoxic conditions induced a 15-fold 
increase of mir-125b in VSMC compared with ASMC, 
which did not show a significant change. In the author’s 
opinion this could explain the lack of VEGF-A upregula-
tion in hypoxic venous SMC [37]. Other relevant miRNA 
include miR-143 and 145, which appear to have signifi-
cant roles in SMC fate and plasticity [38, 39]. Adding 
complexity to the VSMC-EC interaction is the existence 
of intercellular nanotubes that shuttle VSMC derived 
miR-143 and 145 to EC and thereby influence EC biology 
[40]. This mechanism, at least in part, was triggered by 
TGFβ and vessel stress [40].
Further complicating is the finding that significant dif-
ferences between EC from various vascular beds exist 
[41]. There appear to be even differences in the phe-
notypes of aortic valve EC on the ventricular site when 
compared to the aortic site. In vitro shear-stress experi-
ments revealed that waveforms simulating the ventricular 
flow pattern selectively upregulated the atheroprotective 
transcription factor Kruppel-like factor 2 (KLF2), while 
suppressing the pro-inflammatory chemokine monocyte-
chemotactic protein-1 (MCP-1) in EC [42].
Separately, bone morphogenetic protein (BMP) sign-
aling has been found relevant for a variety of pathways 
involved in EC biology. Heterogeneous transcriptional 
activity seemed to correlate with vasculature undergo-
ing hemodynamic alterations [43]. BMP signaling is 
connected to other major signaling pathways including 
Notch, WNT, and is altered in response to hypoxia [44].
Locoregional differences in miRNA expression patterns 
as a function of flow disturbances have been investigated, 
coining the term “flow-sensitive miRNA” or “mechano-
miRNA” [45]. miRNAs such as, miR-10a, miR-19a, 
miR-23b, miR-17-92, miR-21, miR-663, miR-92a, miR-
143/145, miR-101, miR-126, miR-712, miR-205, and miR-
155 are counted amongst those mechano-miRs [45].
In addition, there appear to be differences in siRNA 
susceptibility between EC and VSMC and possibly even 
between the various VSMC fractions under identical 
transfection conditions [9, 10].
All these biological differences help explain the vary-
ing loco-regional responses to vascular injury including 
atherosclerosis, postangioplasty restenosis and vein graft 
disease [34]. These data underscore the importance of a 
comprehensive characterization of the specific target cell 
subtype and the spatial differences with the cell subtype. 
Further, it is important to understand the pathophysi-
ologic consequences that a specific intervention inflicts 
on these cells. This includes the effects of RNAi therapy 
itself including the effects of the transfection reagents 
used.
RNAi delivery methods
Systemic, naked siRNA administration without technol-
ogy to target specific cells types leads to renal siRNA 
secretion within 20 min as well as rapid plasma nucle-
ase degradation. In addition, significant degradation and 
phagocytosis via the reticuloendothelial system occurs 
which also shortens the siRNA’s systemic half-life [46].
In parallel, several chemical modifications to the RNA 
have been introduced including locked nucleic acid tech-
nology (LNA), in which an additional covalent bond 
within the RNA backbone is formed. This has proven to 
improve stability to the RNA molecule and protection 
from phagocytosis [47, 48].
Liposomes are spheres consisting of customizable 
phospholipid layers that can be used for drug delivery. 
Liposomes widely used to facilitate diagnostic and exper-
imental siRNA silencing vitro and are one of the most 
commonly used transfection modality [9, 49, 50]. How-
ever, liposomal siRNA formulations also undergo sig-
nificant uptake by macrophages, liver and spleen (RES) 
limiting the ability to successfully reach the target genes 
in  vivo. In addition, problems with toxicity, immune 
response, non-specific uptake, and the risk of off-side 
effects have been raised [9, 49, 51, 52].
The introduction of poly(ethylene glycol) (PEGylation) 
into liposomal formulations is another commonly per-
formed process aimed at improving drug delivery effi-
cacy. PEGylation is thought to confer some protection 
from mononuclear phagocytosis through the creation of 
a protective hydrophilic film on the surface of the lipo-
some and decrease renal clearance due to a size increase 
of the liposomal complex [53–57].
Cationic polymers such as polyethyleneimine (PEI) can 
also be used to complex RNA complexes and improve 
transfection efficiency into vascular cells in  vitro and 
in  vivo [28, 58–60]. The positive surface charge of PEI-
siRNA complexes may be utilized for adsorption onto 
vascular materials [58]. Incorporation of albumin into 
PEI-siRNA complexes provided protection from extra-
cellular endonucleases and improved internalization and 
silencing efficiency in vitro [61]. However, PEI has been 
shown to have significant impact on global gene expres-
sion, leading to changes in 213 genes in human aortic 
SMC. These genes were mostly related to inflammation 
and immune response. These findings illustrate how PEI 
alone could affect the results of the RNAi therapy [29].
Another promising modality is RNAi contain-
ing nanoparticles. Some of these nanoparticles have 
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self-assembling properties. The individual composition 
of these nanoparticles is highly customizable and can be 
adjusted to the specific needs of the therapy approach 
[62–66]. These nanoparticles can consist of degradable, 
biologically compatible materials such as poly(lactide-c-
glycolide) (PLGA) [67]. The polymer’s degradation profile 
might allow for sustained RNAi release for vascular deliv-
ery [68, 69]. Polymer blends and co-polymers may also 
facilitate sequential RNAi release.
RNAi encoded in lentiviral and adenoviral vectors was 
successfully delivered to cardiovascular cells and other 
tissues [13, 65, 70–74]. Due to concerns of immuno-
genicity associated with older adenoviral constructs and 
possible insertional mutagenesis by lentiviruses, novel 
adenovirus associated viruses (AAV) have been devel-
oped. AAV have shown some promise for anti-angiogenic 
therapies for human retinal diseases [75–77]. While AAV 
is a powerful tool, there is ongoing research to develop 
modified AAV surface capsids for cell-specific RNAi 
delivery [78].
Many reviews exist that provide comprehensive over-
views of RNAi vectors, chemical modifications and trans-
fection agents including detailed capabilities and current 
limitations of either technology [50, 79, 80]. For the pur-
pose of this review we will focus on approaches pertain-
ing to vascular RNAi delivery.
Results of vascular RNAi therapy for vascular injury 
remodeling
Local intraluminal RNAi delivery
Depending on the target cell (EC versus VSMC), local 
intraluminal RNAi delivery represents a logical and sim-
ple approach. Obvious challenges are the interaction of 
RNAi and its delivery vehicles with the components of 
blood, penetration in the cellular and non-cellular layers 
of the vessel wall, and washout from the site of delivery.
Single application can be accomplished via injection 
with or without distal occlusion or possibly from balloon 
catheters. In the setting of vein bypass grafting the RNAi 
solution may be infused into the graft. Similarly, brief dis-
tal arterial occlusion and target vessel distention is feasi-
ble in certain settings and may be used to enhance RNAi 
delivery.
Utilizing above approach PEI complexed TSP-2-siRNA 
was successfully administered to the denuded wall of 
rat carotid arteries and yielded a lasting silencing effect. 
While this resulted in desirable changes in transforming 
growth factor–beta (TGF-β) and matrix metalloprotein-
ase-9 (MMP-9) signaling, as well as anti-inflammatory 
M2 macrophage polarization, it did not affect intima/
media ratios [59].
In contrast, intraluminal siRNA targeting transcrip-
tion factor activation transcription factor-4 (ATF-4), a 
downstream target of the mitogen fibroblast growth fac-
tor-2 (FGF-2) in balloon injury rat carotid arteries did 
lead to a measurable decrease in intimal hyperplasia [81].
Likewise, adenovirus mediated silencing of A disinteg-
rin and metalloproteinase with thrombospondin motifs-7 
(ADAMTS-7), a metalloproteinase reduced intimal 
VSMC proliferation in a rat model of balloon-induced 
vascular injury [82].
Several studies involving miR expression modulation 
in injured vascular walls have yielded some encourag-
ing results. Amongst others, miR- 24 and miR-29b were 
found to be decreased in balloon-injured rat carotid 
arteries [73, 83]. MiR-24 delivery to the carotid artery 
wall decreased IH possibly through inhibiting Wnt4 sign-
aling [73]. Local miR-29b delivery decreased IH forma-
tion possibly via downregulation of MMP-2 and myeloid 
leukemia cell differentiation MCL-1, a known inhibitor 
of apoptosis [83]. Similarly, delivery of miR-34c to the rat 
carotid artery after catheter injury has shown to attenuate 
stem cell factor expression and subsequently mitigated 
formation of IH [84]. MiR-132 delivery also mitigated IH 
via inhibition of VSMC proliferation in a carotid artery 
injury model [85]. However, thus far it has been difficult 
to translate findings of IH reduction from rodent mod-
els into large animal models or even human studies. This 
may be in part due to the thicker muscular vascular wall, 
limiting a homogenous transmural cell transfection in 
larger animals as well as possible differences in the indi-
vidual species’ cell biology.
Sustained, transluminal, local delivery has been 
attempted by using RNAi coated, implanted stents/stent 
grafts. Plasmid DNA has been successfully transferred to 
the arterial wall in a pig stent-angioplasty model [86]. In 
line with this work, layer-by-layer (LBL) technology has 
emerged as an effective way to deposit multiple thin films 
of coating on surfaces and has shown to be one way to 
enhance sustained oligonucleotide delivery to the vas-
cular wall from stent surfaces in vitro [87, 88]. Likewise, 
LBL technology utilizing siRNA nanoparticles allowed 
for sustained ex vivo siRNA transfer to the porcine arte-
rial wall [89].
Alternatively, various biodegradable coatings such as 
poly(d,l-lactic-co-glycolic acid) (PLGA) and poly (l-lac-
tide) (PLLA) are FDA approved as stent coatings that 
potentially could provide a sustained release RNAi to the 
vessel wall [90–93]. These materials are biocompatible 
and predictably degrade fully over time.
Local perivascular RNAi delivery
Perivascular delivery may have advantages over luminal 
administration in that the RNAi delivery vehicle is not 
exposed to blood and systemic arterial pressures. This 
could have benefits with regards to sustained delivery. 
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Vasa vasora of large arteries and veins may aid in the 
perivascular delivery. Unwanted washout to other regions 
of the circulation may also be less. Further, if VSMC are 
primarily targeted, a perivascular approach may limit EC 
exposure to RNAi and its vehicle/vector.
Several studies have shown that perivascular delivery of 
RNAi is feasible and can result in measurable histologic 
effects with regards to IH formation. Similar to intralu-
minal delivery, ADAMTS-7 (a disintegrin and metallo-
proteinase with thrombospondin motifs 7) silencing after 
perivascular delivery of ADAMTS-7 siRNA in pluronic 
gel mitigated IH in injured rat arteries [82, 94].
Silencing of STAT-3, a transcription factor of multi-
ple receptors also inhibited VSMC and decreased IH via 
expression of Bcl-2 and cyclin D1 in rat vein grafts with-
out increases in apoptosis. siRNA was encapsulated with 
the liposomal transfection reagent Lipofectamine and 
deployed in a “Bioprotein gel” that was applied onto the 
adventitia of the rat vein grafts [95].
Likewise, siRNA targeting the heparin-binding growth 
factor midkine (MK) mixed with atelocollagen was 
administrated to the external wall of rat vein grafts. MK 
silencing decreased immune cell recruitment, and cell 
proliferation within MK siRNA-treated vein grafts [96].
Systemic RNAi delivery
Primary systemic delivery requires large doses of RNAi 
and its delivery vehicle thus increases cost, and the 
chance of off-site effects and toxicity.
In a mouse model of carotid injury the transcrip-
tion factor GATA-2 was found to be reduced. GATA-2 
regulates multiple EC specific genes as well as miR-126 
and miR-221. Systemic miR-126-coupled nanoparticles 
enhanced miR-126 availability in the carotid artery and 
improved re-endothelialization of injured carotid arteries 
in vivo [97].
Independently, miR-181b has been shown to inhibit 
TNF-α induced downstream NF-κB signaling. Includ-
ing vascular cell adhesion protein 1  (VCAM-1), inter-
cellular adhesion molecule-1 (ICAM-1), E-selectin, and 
tissue factor. In a rodent model of photochemical injury-
induced carotid artery thrombosis, systemic miR-181b 
delivery conferred some protection from thrombin-
induced EC activation and arterial thrombosis [98].
Cell specific siRNA delivery
The endothelial cell biology has been well studied and 
various EC specific (CD31, TIE2, ICAM-1, VCAM-1, 
E-selectin) cell surface markers have been described in 
the literature as targets to provide a more directed, cell 
specific RNAi therapy [99–103].
Recent results showed that cationic lipoplexes can be 
designed that result in a predominant uptake into the 
vascular endothelium and thereby minimizing offsite-
target effects [102]. Further work yielded a formulation 
that provided preferential pulmonary endothelial uptake 
[104].
While activated, VCAM-1 expressing EC were success-
fully targeted by PEGylated antibody-targeted lipoplexes 
in vitro. However, these promising results did not result 
in successful silencing in vivo [101].
While not exclusive, chemokine receptor CXCR-4 is 
constitutively expressed in EC. Peptide carriers as RNAi 
vehicles that contain a CXCR-4 ligand increased efficacy 
of VEGF-siRNA to EC [105].
Another intriguing approach resulted from data of an 
in  vivo phage display in the setting of a partial carotid 
ligation model of flow-induced atherosclerosis in mice 
[100].
This led to the identification of two peptides (CLIR-
RTSIC and CPRRSHPIC) that specifically bind to EC 
exposed to turbulent flow in pro-atherogenic regions. 
These peptides were conjugated to polyethylenimine 
(PEI)-polyethylene glycol (PEG) to generate polyplexes 
containing ICAM-1 siRNA. CLIRRTSIC polyplexes car-
rying si-ICAM-1 specifically bound to mouse endothe-
lium and silenced ICAM-1 expression in disturbed flow 
regions in a mouse model [100].
It remains to be seen if successful transfection of a 
rodent arterial wall can be translated into larger animal 
studies or even humans given the significant differences 
in wall thickness. Even if a similar transmural transfec-
tion result is achieved, it may come at the risk of higher 
toxicity and off-site effects given as larger doses of 
transfection agents and RNAi oligonucleotides may be 
required.
Target choice
Vascular injury is characterized by a dramatic upregula-
tion of thousands of genes within a matter of hours as 
demonstrated in a study of vein graft implantation in 
canine [106]. Over the following weeks these gene expres-
sion changes largely approach baseline [106]. Despite this 
apparent gene expression “near-normalization” after 4 
weeks, the process of vascular remodeling and thus the 
growth of vascular lesions continues past that point. It 
is therefore of interest to have the option of a sustained 
release of RNAi to the vascular wall to change gene 
expression past the immediate period of graft implanta-
tion or endovascular intervention. Analysis of gene net-
works revealed significant signaling redundancy, which 
suggests it might be prudent to silence multiple genes 
simultaneously and/or sequentially in order to optimize 
the clinical effect of siRNA therapy. This became evident 
in a recent rat carotid artery angioplasty model, in which 
the extracellular matrix protein thrombospondin-2 was 
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silenced through single intravascular siRNA administra-
tion. Anti-TSP-2 siRNA complexed with PEI resulted in 
TSP-2 protein level suppression for at least 21 days. This 
resulted in changes in downstream transforming growth 
factor–beta (TGF-β) and matrix metalloproteinase-9 
(MMP-9) signaling and increased M2 macrophage polar-
ization. However, no significant changes in the intima/
media ratios were noted [59]. This data underscores the 
importance of target gene selection. While in this case, 
TSP-2 silencing yielded the anticipated downstream sign-
aling effect and even a desirable macrophage phenotype 
switch, it did not result in a histologically relevant effect.
Given the discussed issues of cell specific RNAi deliv-
ery, target gene choice becomes a conundrum. Silencing 
of the target gene should result in a robust alteration in 
the biology of the targeted cell. In contrast, inadvertent 
target gene silencing in bystander cells should not impede 
those cells’ inherent biological activities. For example, 
the cell cycle and apoptosis regulator survivin (SVV) is 
highly upregulated in SV-VSMC the setting of IH [13, 
107]. This appears to promote the proliferative, apopto-
sis resistant and migratory VSMC phenotype responsible 
for IH. In  vitro silencing of SVV in SV-VSMC resulted 
in a cell cycle block with a subsequent decrease in pro-
liferation. While it did not increase the rate of apoptosis 
in SV-VSMC to noxious stimuli, it did impair SV-VSMC 
migration.
In contrast, it has been shown, that overexpression of 
SVV in EC resulted in increased viability and migratory 
capability, but reduced apoptosis. SVV overexpressing 
EC were also associated with higher levels of angiogen-
esis in vivo [13, 107–110].
One of those candidate genes that differentially 
affects biology of EC and VSMC may be MARCKS 
(myristoylated alanine rich protein kinase C substrate) 
[111–114]. MARCKS silencing in VSMC attenuated 
proliferation and migration, while in EC these two cell 
functions appeared unaltered [114]. This of course does 
not preclude, that other EC functions may be affected by 
MARCKS silencing that could be relevant for vascular 
injury remodeling.
Conceptually an intriguing group of target genes are 
inflammatory cytokines and extracellular matrix pro-
teins that are secreted by both, EC and VSMC. Arguably, 
silencing these targets in both cell fractions may prove 
beneficial.
Translational potential and steps needed to get 
there
Establishing methods to reliably transfect specific cells 
of the vascular wall in a controlled and sustained fashion 
could have wide ranging clinical benefits. Naturally, ath-
erosclerosis, aneurysmal disease, and intimal hyperplasia 
come to mind as primary disease entities. However, there 
are a variety of other clinical scenarios in which transient 
modulation of local vascular biology could be of great 
benefit. For instance it would be highly desirable to be 
able to increase endothelial barrier function in the set-
ting of systemic inflammatory response syndrome and/
or sepsis. Excessive vascular permeability and capillary 
leak lead to local edema with subsequent tissue hypoxia 
and acidosis. Pulmonary hypertension is another major 
cardiovascular condition that may be amenable to RNAi 
therapy [63, 115].
Taken together, the medical community would greatly 
benefit from the translation of the discussed pre-clini-
cal studies to tangible medical therapies. Based on the 
existing data it appears that EC and macrophages cur-
rently might be the most promising target cells with 
regards to cell specific RNAi delivery. Both cell-types 
possess characteristic surface markers that could serve 
as receptors/ligands for cell specific RNAi delivery. Spe-
cific next steps towards clinical application also have to 
involve the transition from rodent to large animal mod-
els. While these are costly, they allow crucial insight 
in how to address larger vessel structures, circulating 
blood volumes, and flow patterns, more consistent with 
humans.
It seems pertinent to further optimize delivery of RNAi 
and develop methods for controlled sustained release. 
For a single local application, ligand-coupled nanopar-
ticles containing RNAi or directly ligand-conjugated 
RNAi in combination with transcatheter administration 
might be a reasonable option. For systemic administra-
tions as in the case of atherosclerosis, it might be use-
ful to deploy receptor/ligand-RNAi constructs aimed 
at epitopes expressed in vascular lesions to direct RNAi 
preferentially to sites of high disease burden. Advances in 
RNAi structure design such as LNA have already yielded 
increased protection from enzymatic degradation and 
thereby increasing RNAi serum half-life [116]. Advances 
in technology to protect RNAi from non-specific tissue 
uptake (e.g. liver) are necessary to make systemic RNAi 
therapy more efficacious. Propensity of macrophages to 
take up RNAi complexes may in fact aid in a therapeutic 
approach for atherosclerosis. Thus, modulation of mac-
rophage activity appears to be a promising approach as 
discussed above.
For sustained RNAi release approaches, perivascu-
lar and RNAi delivery from implantable cardiovascular 
devices may prove successful. As discussed before, sev-
eral biologically compatible polymers exist that could 
serve as a depot for RNAi. Trapping RNAi in biodegrad-
able materials with programmable degradation/release 
patterns needs to be further explored; specifically for car-
diovascular applications.
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In the opinion of the authors, it is important to first 
establish RNAi as a safe and programmable tool to 
modulate biological processes. As we start to under-
stand RNAi-related challenges such as sequestration 
in liver, lung and macrophages, it might be judicious to 
first investigate the effects of RNAi in the lung vascula-
ture and macrophages. If the desired results are achieved, 
increased resources could be dedicated to tackle other 
challenges relating to RNAi delivery to the vascular wall.
Conclusions
As the understanding of vascular physiology and dis-
ease expanded over the past decades, it has become 
evident that significant loco-regional differences in vas-
cular cell biology exist. Likewise, the technologies around 
RNAinterference have become increasingly sophisti-
cated. However, anatomical barriers such as those found 
in large human blood vessels have not been adequately 
addressed. Also, off-site effects of RNAi therapy adjuncts 
can be significant and have to be carefully considered. 
Moreover, the ‘correct’ target gene choice for the indi-
vidual vascular disease has yet to be made and it may be 
required to silence multiple genes in a synergistic fashion 
in order to achieve clinically relevant results. The reli-
able translation of promising in  vitro or rodent animal 
data to large animal or human studies still has to occur. 
While multiple preclinical studies reported encour-
aging results of RNAi delivery to the vascular wall, it 
remains to be seen if a single target can be sufficient to 
the achieve clinically desirable changes in the injured 
vascular wall in humans. As discussed, the only existing 
clinical trial of vein graft treatment with oligonucleotides 
(PREVENT III) targeting E2F has failed to show clinically 
relevant results [26, 27]. While i.v. RNAinterference has 
been shown to be feasible for some organs; cell-specific, 
transmural vascular siRNA or miRNA delivery remains 
an unmet challenge. Off-target effects of RNAi and non-
specific effects of transfection agents can significantly 
alter expression of a broad range of genes, which in turn 
could adversely influence the RNAi therapy results [29]. 
Successful therapies for vascular diseases may require the 
collaboration of an interdisciplinary team of geneticists, 
vascular biologists, chemical engineers and clinicians. 
Given the great burden that cardiovascular diseases 
inflict upon society, it is imperative to find new treatment 
opportunities. RNAi may be a technology that, when cus-
tomized appropriately, could help ease that disease bur-
den in the future.
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